RAMM

PHARMA

RAMM Pharma Commences Sales of NettaPet™ CBD Enriched Super Premium Quality Dog Food with Strong Pre-Order Demand

Toronto, Ontario (April 9, 2021) – RAMM Pharma Corp. (including its wholly owned subsidiaries, the "**Company**" or "**RAMM") (CSE: RAMM) (OTC: RAMMF)**, a leader in plant-derived cannabinoid pharmaceutical products, is pleased to announce that it has commenced commercial sales of its NettaPet™ cannabidiol ("CBD") enriched super premium quality dog food. NettaPet is the first product to be commercialized by RAMM's wholly owned subsidiary NettaLife which focuses on the production, commercialization and export of CBD enriched pet food, specialty pharmaceutical, cosmetic and other products for animals, as well as research & development in support of total animal wellbeing. Additional information can be found on NettaLife's website www.nettalife.com.

40 Tons of NettaPet™ was produced in RAMM's maiden production run, over 50% of which was pre-sold to wholesalers and distributors providing nation-wide distribution for NettaPet™ products across Uruguay. Commercial-scale production will now continue for all three formulations to meet consumer demand.

"We are pleased to commence sales of our super premium dog food and with the strong demand that has been seen without having commenced any marketing initiatives. We are eager to expand this business within Uruguay and internationally," stated Jack Burnett, Chief Executive Officer.

NettaPet™ CBD enriched super premium quality dog food, approved and registered by the Uruguayan Ministry of Agriculture, Livestock and Fisheries (MGAP) is available in three formulations – Puppy, Adult and Senior dog. Each of the three formulations is available in 3.420kg, 12kg and 22kg formats. NettaPet™ dog food features only premium ingredients and natural flavours, with no artificial flavours or colouring. Only premium chicken and beef protein are used, with a minimum protein of 26% in the Adult formulation and 30% in the Puppy formulation.

Uniquely designed, high-quality packaging preserves freshness of the food and allows NettaPet™ dog food to be made without any artificial preservatives. NettaPet™ packaging features triple layer construction and aluminized interior with a zip-lock closure and humidity valve, all of which keep the food fresh even after it has been opened.

NettaPet™ Dog Food Formulations (Puppy, Adult and Senior)

Animal CBD, Pet Food & Veterinary Market Information
The global pet food market size was valued at USD $87.1 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 4.5% from 2019 to 2025 (Grand View Research).

The Pet CBD market is expected to reach USD $1.7 billion by the end of 2025, driven by recent research-based knowledge on CBD's potential benefits, combined with ongoing product innovations from CBD companies and increased consumer awareness and demand for pet CBD products. Growth is being driven by pet owners looking for natural alternatives for pets' medical ailments, especially anxiety, pain, or other serious conditions that have not responded well to other treatments (Brightfield Group, 2020).

The global veterinary medicine market size was estimated at USD $29.2 billion in 2020 and is expected to expand at a compound annual growth rate of 7.4% from 2021 to 2028 (Grand View Research).

The global pet food market size was valued at USD $87.1 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 4.5% from 2019 to 2025 (Grand View Research).

About NettaPet™
The Nettalife team has worked with experts in pet nutrition to create tasty and healthy recipes for the NettaPet™ line. Each formulation contains the ideal concentrations of nutrients for each profile (Puppy, Adult and Senior) recommended by the reference associations of the United States (AAFCO) and Europe (FEDIAF). Each formulation includes high-quality hemp biomass providing CBD, vitamins A, C and D, amino acids, fatty acids and natural fiber. NettaPet™ products are made from premium hemp CBD with less than 0.2% THC and meet Uruguayan federal regulations for export to most Latin American countries. A cat food range is currently under development along with a pipeline of other products under development.

About NettaLife™
NettaLife is a leading developer of cannabis-based products for pets and large animals. NettaLife's products are currently manufactured under two main brands - NettaPet™ which is focused on nutrition, and NettaVet™ which is focused on the development of specialized veterinary and medicinal products. In

November 2019, NettaPet™ became the first cannabis-based pet food to be approved and registered by the Ministry of Agriculture, Livestock and Fisheries (MGAP). NettaLife is led by a team of pioneers in the development of the pet and animal care industry in Uruguay and Latin America with significant veterinary industry expertise and pet-focused business acumen.

About RAMM Pharma Corp.

Led by renowned cannabis industry experts and backed by successful pioneers in the cannabis sector, RAMM is a leader in the field of cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other cannabis-based products. Founded in 1988 in Montevideo, Uruguay, the Company is a well established pharmaceutical and medical product business that has developed medically registered and approved plant-derived cannabinoid pharmaceutical products. The Company currently has multiple approved and registered products that have been authorized for sale in Uruguay and compassionate use in several Latin American countries, as well as a pipeline of new products in various stages of approval and development produced in the Company's state of the art Good Manufacturing Practice (GMP) certified cannabis formulation facility. Further to its industry leading activities in the cannabis sector, the Company operates a successful pharmaceutical, cosmetic and nutraceutical product development and medical services business which has been servicing the local market for 30 years.

RAMM Pharma Corp. includes wholly owned subsidiaries Medic Plast SA, Yurelan SA, Glediser SA and Ramm Pharma Holdings Corp.

Additional information about the Company is available at www.rammpharma.com.

For further information, please contact:

Guillermo Delmonte
Chief Operating Officer
+598 92 223 131
info@rammpharma.com

Cautionary Note Regarding Forward-Looking Information

*This news release contains "forward-looking information" and "forward-looking statements" (collectively, "**forward looking statements**") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking statements relate, among other things, the size of the Pet CBD market, the Company's strategies and objectives, and future expansion plans.*

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: efficacy of the Company's new product offerings; the expected size of the Pet CBD market and general consumer demand; the expected timelines associated with the production, roll-out and availability of the Company's new products; the ability to meet increased demand *for the Company's products, changes in prices of required commodities; the impact of COVID-19 on the Company's workforce, suppliers, partners, customers, and other essential resources and what effect those impacts, if they occur, would have on the Company's business and operations; future growth potential of the Company; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Uruguayan, Latin American, and international medical and recreational cannabis and CBD markets and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in Uruguay or internationally; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.*

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.